Home › Free Stock Grades › BMRN
BioMarin Pharmaceutical Inc. (BMRN) Stock Grade
BMRN · Healthcare
A
Market Cap
$11.5B
P/E Ratio
32.7
Revenue Growth (YoY)
+12.9%
Net Margin
10.8%
Return on Equity
5.7%
Dividend Yield
None
About BioMarin Pharmaceutical Inc.'s fundamentals
BioMarin Pharmaceutical is a $11.5 billion biotechnology company with revenue growing at 12.9% year-over-year and a net profit margin of 10.8%, indicating operational profitability despite the capital-intensive nature of drug development. The company trades at a P/E ratio of 32.7, reflecting investor expectations for future growth, while its return on equity of 5.7% suggests modest efficiency in generating profits from shareholder capital. As a development-stage biotech firm, BioMarin does not currently pay a dividend, instead reinvesting earnings into research and development.